Van Lanschot Kempen Logo
  • Home
  • Solutions
  • News & knowledge
  • About us
Apr 2017
Nanobiotix logo
Joint global coordinator
Joint bookrunner
25.1 million
Accelerated bookbuild offering

Nanobiotix

Nanobiotix is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer

  • Placement of 1,596,527 new shares, representing 10% of Nanobiotix’ pre-deal outstanding share capital
  • Issue price of €15.75 per share represented a limited 1.4% discount versus the year-to-date average closing price
  • Kempen & Co acted as Joint Global Coordinator and Joint Bookrunner in this transaction
 
 

Fully focused on your future

Private Banking

  • Offices
  • Business professionals
  • Executives
  • Doctors
  • Entrepreneurs
  • Wealth management
  • Conditions
  • Private Banking - Belgium
  • Private Banking - Switzerland

Professional Solutions


Investment Management


Investment Banking



© Van Lanschot Kempen 2022
Security
Privacy & cookies
Disclaimer